ONE-LUNG VENTILATION PATIENTS: CLINICAL CONTEXT OF ADMINISTRATION OF DIFFERENT DOSES OF DEXMEDETOMIDINE

PACIJENTI SA VENTILACIJOM JEDNOG PLUĆNOG KRILA: KLINIČKI KONTEKST PRIMENE RAZLIČITIH DOZA DEKSMEDETOMIDINA

Hui Jiang1,#, Yu Kang2,#, Chunlin Ge1, Zhenying Zhang1, Yan Xie1

1Department of Anesthesiology, Xuhui District Central Hospital, Shanghai, China
2Department of Anesthesiology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Summary

Background: Open and endoscopic thoracic surgeries improve surgical exposure by One-lung ventilation (OLV). The aim of this study was to investigate the effects of different doses of dexmedetomidine on inflammatory response, oxidative stress, cerebral tissue oxygen saturation (SctO2) and intrapulmonary shunt in patients undergoing one-lung ventilation (OLV).

Methods: Seventy-five patients undergoing open pulmonary lobectomy in our hospital from January 2016 to December 2017 were enrolled and randomly divided into high-dose dexmedetomidine group (group D1, 1 µg/kg, n=25), low-dose dexmedetomidine group (group D2, 0.5 µg/kg, n=25) and control group (group C, n=25). Then, arterial blood and internal jugular venous blood were taken before anesthesia induction (T0) and at 15 min after two-lung ventilation (T1) and 5 min (T2) and 30 min (T3) after OLV for later use. Next, the changes in hemodynamic parameters [mean arterial pressure (MAP), heart rate (HR) and pulse oxygen saturation (SpO2)] of patients were observed in each group. Enzyme-linked immunosorbent assay (ELISA) was carried out to detect serum inflammatory factors such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) and oxidative stress indicators [superoxide dismutase (SOD) and malondialdehyde (MDA)]. The changes in SctO2, arterial partial pressure of oxygen (PaO2) and intrapulmonary shunt Qs/Qt (a measurement of pulmonary shunt: right-to-left shunt fraction) were observed. Additionally, the changes in lung function indicators like lung dynamic compliance (Cdyn) and airway peak pressure (Ppeak) were determined.

Address for correspondence:
Yan Xie, MM
Department of Anesthesiology, Xuhui District Central Hospital, 966 Huaihai Middle Road, Shanghai 200031, China
Phone: 86013661663454
e-mail: xy3326357@163.com

# Hui Jiang and Yu Kang contributed equally to this work
Introduction

One-lung ventilation (OLV) is commonly used for open and endoscopic thoracic surgeries to improve surgical exposure. Hypoxic pulmonary vasoconstriction (HPV) shunts blood from the non-ventilated lung to the non-surgical lung, thus maintaining adequate oxygenation (1, 2). Thoracic epidural anesthesia (TEA) is the most commonly used analgesia technique in patients receiving thoracic surgeries for lungs. It has been proved that strong inhalation anesthesia inhibits HPV in a dose-dependent manner, thereby altering the oxygenation during OLV and resulting in increased shunt and impaired oxygenation (3, 4). Studies have revealed that the development and progression of inflammatory response and oxidative stress are promoted in the peri-operative period. Dexmedetomidine is a highly selective and very potent α2-adrenergic agonist with antioxidant properties, metabolized in the liver and approved to be used in intensive care units as a sedation and anesthesia assistant, with sedative and analgesic effects (5).

A previous study demonstrated that dexmedetomidine lowers the high levels of malondialdehyde (MDA) and hypoxanthine formed after the application of tourniquets in upper-limb surgeries, with an obvious effect (6). Dexmedetomidine has analgesic, anti-inflammatory and sedative effects, on which many clinical and experimental studies have been conducted in recent years (7, 8). Moreover, research of the role of dexmedetomidine in ischemic and toxic inflammation models has revealed that dexmedetomidine has an anti-inflammatory effect, which evidently inhibits the production of inflammatory factors including tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), IL-6 and macrophage inflammatory protein 2, and avoids damage to organs. Furthermore, it has been reported that dexmedetomidine prominently relieves lung inflammation in a rat model of ventilator-induced lung injury. Shen et al. (9) measured the levels of TNF-α and IL-6 in the case of lung injury induced in experimental models and proved that the production of these cytokines is reduced to the utmost in lung tissues after administration with dexmedetomidine. A study pointed out that mouse

Results: There were no statistically significant differences in the MAP, HR and SpO2 among three groups at each observation time point (P>0.05). At T2 and T3, the levels of serum IL-6, TNF-α and IL-8 were obviously decreased in group D1 and D2 compared with those in group C (P<0.05), and the decreases in group D1 were overtly larger than those in group D2, and the decreases at T3 were markedly greater than those at T2 (P<0.05). In comparison with group C, group D1 and D2 had notably reduced levels of serum reactive oxygen species (ROS) and MDA (P<0.05) and remarkably increased SOD content (P<0.05) at T2 and T3, and the effects were markedly better in group D1 than those in group D2. Besides, they were significantly superior at T3 to those at T2 (P<0.05). The SctO2 in group D1 and D2 was evidently lowered at T2 and T3 compared with that at T0, and the decrease in group D1 was distinctly smaller than that in group D2 (P<0.05). The Qs/Qt was significantly lower in group D1 and D2 than that in group C at T2 and T3 (P<0.05), while the PaO2 content was notably raised (P<0.05), and the decrease and increase were significantly larger in group D1 than those in group D2, and they were obviously greater at T3 to those at T2 (P<0.05). At T0 and T1, no significant differences were detected in the Cdyn, Pplat and Ppeak among three groups. At T2 and T3, the Cdyn was significantly elevated, while the Pplat and Ppeak overtly declined (P<0.05), and group D1 had greater changes in comparison with group D2, and the changes were obviously more evident at T3 to those at T2 (P<0.05).

Conclusions: Dexmedetomidine effectively ameliorates inflammatory response and oxidative stress, lowers oxygenation, Qs/Qt and the decrease in SctO2 and improves lung function during OLV, with good efficacy.

Keywords: dexmedetomidine, one-lung ventilation, inflammatory response, oxidative stress, cerebral tissue oxygen saturation, intrapulmonary shunt

Rezultati: Nije bilo statistički značajnih razlika u MAP, HR i SpO2 između tri grupe u svakoj vremenskoj tački posmatranja (P>0.05). Na T2 i T3, nivoi serumskih IL-6, TNF-α i IL-8 su očigledno bili smanjeni u grupi D1 i D2 u poređenju sa onima u grupi C (P<0.05), a smanjenje u grupi D1 je bilo očigledno veće od oni u grupi D2, a smanjenja na T3 bila su značajno veća od onih u T2 (P<0.05). U poređenju sa grupom C, grupe D1 i D2 su imale značajno smanjene nive serumskih reaktivnih vrsta kiseonikosa (ROS) i MDA (P<0.05) i značajno povećan sadržaj SOD (P<0.05) na T2 i T3, a efekti su bili znatno bolji u grupi D1 od onih u grupi D2. Osim toga, oni su bili značajno bolji na T3 u odnosu na one na T2 (P<0.05). SctO2 u grupi D1 i D2 je evidentno smanjen na T2 i T3 u poređenju sa onim u T0, a smanjenje u grupi D1 je bilo znatno manje nego u grupi D2 (P<0.05). Ks/Kt je bio značajno niži u grupi D1 i D2 nego u grupi C na T2 i T3 (P<0.05), dok je sadržaj PaO2 bio značajno povišen (P<0.05), a smanjenje i povećanje su značajno veće u grupi D1 od onih u grupi D2, i očigledno su bili veći na T3 u odnosu na one u T2 (P<0.05). Na T0 i T1, nisu otkrivene značajne razlike u Cdyn, Pplat i Ppeak između tri grane. Na T2 i T3, Cdyn je bio značajno povišen, dok su Pplat i Ppeak izrazito opali (P<0.05), a grupa D1 je imala veće promene u poređenju sa grupom D2, a promene su očigledno bile očiglednije na T3 u odnosu na one na T2 (P<0.05).

Zaključak: Deksmedetomidin efikasno ublažava inflamatorni odgovor i oksidativni stres, smanjuje oksigenaciju, Ks/Kt i smanjenje SctO2 i poboljšava funkciju pluća tokom OLV, sa dobrom efikasnošću.

Ključne reči: deksmedetomidin, ventilacija jednog plućnog krila, inflamatorni odgovor, oksidativni stres, saturacija cerebralnog tkiva kiseonikom, intrapulmonalni šant
liver ischemia-reperfusion (I/R) injury results in oxidative stress, which is manifested as enhanced MDA, an oxidant and reduced superoxide dismutase (SOD), an antioxidant (10). Lung tissues are vulnerable to the harmful effects of hypovolemia, and excessive inflammation and oxidative stress response are detected in a mouse model, including SOD and MDA (11). SOD is ubiquitous, and MDA can resist the effects of SOD, with cytotoxicity. After I/R, the treatment with the antioxidant dexmedetomidine is capable of ameliorating organ oxidative stress and achieving better outcomes. Antioxidant therapy with transmembrane free radical scavengers can improve the prognosis of I/R rats (12). The above findings suggest that dexmedetomidine effectively attenuates inflammatory response and oxidative stress during surgery. The changes in cerebral tissue oxygen saturation \( (S_{ctO2}) \) are measured horizontally, continuously and non-invasively in the peri-operative period through the frontal microvascular system. Additionally, the specific changes in \( S_{ctO2} \) are monitored to provide real-time oxygenation in local tissues during full-circulation arrest, venous cannula obstruction or sudden global hypoxemia in cardiac surgeries. Reduced \( S_{ctO2} \) is considered as an indication of potential hypoxia-induced injury that needs further interventions (13). Evaluating cardiac output and systemic oxygenation sufficiency may have potential value in changing the ventilation mode in the peri-operative period in patients who received the bidirectional Glenn procedure (14).

This study aims to explore the effects of different doses of dexmedetomidine on inflammatory response, oxidative stress, \( S_{ctO2} \) and intrapulmonary shunt in patients receiving OLV. Patients undergoing open pulmonary lobectomy were enrolled in this study, and then hemodynamic parameters, inflammatory factors, oxidative stress indicators, and changes in the \( S_{ctO2} \), arterial oxygen partial pressure \( (PaO_2) \) and \( Qs/Qt \) as well as lung function were observed at different time points, hoping to prove that dexmedetomidine can effectively relieve inflammatory response and oxidative stress, lower oxygenation and \( Qs/Qt \) and improve \( S_{ctO2} \) and lung function during OLV, with good effects. This study provides theoretical and experimental bases for the popularization and application of dexmedetomidine.

**Materials and Methods**

**Clinical data**

Seventy-five patients who underwent open pulmonary lobectomy in our hospital were enrolled as study subjects. Then, the patients enrolled signed the informed content and were randomly divided into high-dose dexmedetomidine group (group D1, 1 \( \mu g/kg, n=25 \)), low-dose dexmedetomidine group (group D2, 0.5 \( \mu g/kg, n=25 \)) and control group (group C, \( n=25 \)). Inclusion criteria: Patients at America Society of Anesthesiologist (ASA) grade I and II, receiving no treatment previously, and not allergic to the drugs used in this study. Exclusion criteria: Patients allergic to the drugs, or with severe cardiovascular or cerebrovascular diseases, or secondary infection complicated with severe abnormal liver or kidney function, or those unable to communicate normally due to severe mental disorders. All clinical specimens in this study were collected with the consent of the patients and their families as per the Declaration of Helsinki. This clinical study protocol was carried out with approval from the Ethics Committee of our hospital. The specific clinical data of patients collected at admission included age, gender, weight, body condition and pathological grade (Table I).

**Therapeutic methods**

Before surgery, all patients were intravenously injected with propofol (1.2 \( mg/kg \)) for anesthesia induction and then with sufentanil (0.5 \( \mu g/kg \)) and rocuronium (0.8 \( mg/kg \)). Next, double-lumen endotracheal intubation was conducted for smooth insertion, during which a fiberoptic bronchoscope was adopted to locate the tracheal tube and ensure good alignment. Thereafter, an anesthesia respirator was connected for mechanical ventilation (VT: 8 \( mL/kg \), RR: 12 times/min, suction ratio: 1:2, inhaled oxygen concentration: 100%, oxygen flow rate: 1 L/min, \( P_{ET} CO_2 \): 40 mmHg), and the respiratory tract was kept clear for sufficient oxygen inhalation. Anesthesia was maintained by jointly injecting with propofol (5 \( mg/kg/h \)) and remifentanil (0.2 \( \mu g/kg/min \), with rocuronium (0.3 \( mg/kg \)) added at intervals. Before surgery, the patients in group D1 were given dexmedetomidine at load capacity of 1 \( \mu g/kg \) using an infusion pump for 10 min and then at 0.5 \( \mu g/kg/h \) until the chest was closed. Those in group D2 were treated with dexmedetomidine at load capacity of 0.5 \( \mu g/kg \) using the infusion pump for 10 min and then at 0.3 \( \mu g/kg/h \) until the chest was closed. Those in group C were given the same amount of normal saline. The position of the patients was changed, and then the fiberoptic bronchoscope was aligned for OLV. The changes in various indexes were observed before anesthesia.

### Table I Clinical data of patients.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group D1</th>
<th>Group D2</th>
<th>Group C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample size</td>
<td>25</td>
<td>25</td>
<td>25</td>
</tr>
<tr>
<td>Number of male patients</td>
<td>12</td>
<td>13</td>
<td>12</td>
</tr>
<tr>
<td>Average age (years old)</td>
<td>45±11</td>
<td>46±12</td>
<td>47±11</td>
</tr>
<tr>
<td>Mean weight (kg)</td>
<td>49±10.5</td>
<td>50±10</td>
<td>48±10.7</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>21.5±3.2</td>
<td>22.1±3.0</td>
<td>21.4±2.8</td>
</tr>
<tr>
<td>ASA grade I</td>
<td>13</td>
<td>14</td>
<td>13</td>
</tr>
<tr>
<td>ASA grade II</td>
<td>12</td>
<td>11</td>
<td>12</td>
</tr>
<tr>
<td>Operation time (min)</td>
<td>89.9±3.5</td>
<td>90.5±5.0</td>
<td>91.4±4.7</td>
</tr>
<tr>
<td>Duration of anesthesia (min)</td>
<td>32.2±3.1</td>
<td>33.5±3.8</td>
<td>34.2±4.6</td>
</tr>
</tbody>
</table>
induction (T0) and at 15 min after two-lung ventilation (T1) and 5 min (T2) and 30 min (T3) after OLV.

Determinations of changes in hemodynamic indexes [mean arterial pressure (MAP), heart rate (HR) and pulse oxygen saturation (SpO2), S\text{a}O\text{2}, PaO2 and intapulmonary shunt Qs/Qt]

The changes in the HR, MAP and SpO2 of patients were recorded in each group before thoracotomy (T1) and at 30 min (T2) after OLV. Arterial blood was sampled for blood gas analysis, the PaO2 was recorded, the intrapulmonary shunt Qs/Qt was calculated, and the S\text{a}O\text{2} was recorded at corresponding time points. Qs/Qt\% = (CcO2 - CaO2)/(CcO2 - CvO2). CcO2 = Hb \times 1.39 \times SaO2 + (PaO2 \times 0.0031), PaO2 = FiO2 \times (Pb - PH2O) - (PaCO2/0.8), CaO2 = (1.34 \times Hb \times SaO2) + (0.0031 \times PaO2), CvO2 = (1.34 \times Hb \times SvO2) + (0.0031 \times PaO2).

Detection of serum inflammatory factors via enzyme-linked immunosorbent assay (ELISA)

After collecting venous blood (5 mL) into Eppendorf (Ep) tubes containing anticoagulant from arms, centrifugation was conducted at room temperature and 3000 g for 15 min, followed by collection of the supernatant. Next, the levels of serum inflammatory factors (IL-6, IL-8 and TNF-\alpha) were measured according to the instruments of the ELISA kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China). Later, the absorbance in each group was read using a microplate reader.

Measurement of serum oxidative stress indexes through ELISA

Venous blood (5 mL) was collected into Ep tubes containing anticoagulant from arms and centrifuged at room temperature and 3500 g for 15 min. Thereafter, the supernatant was collected, and the changes in the content of serum oxidative stress indexes [MDA, SOD and reactive oxygen species (ROS)] were determined according to the instruments of the ELISA kit (Nanjing SenBeiJia Biological Technology Co., Ltd., Nanjing, China). Lastly, the microplate reader was utilized to read the absorbance in each group.

Examination of lung function

Side stream spirometry was adopted to monitor lung function indicators [lung dynamic compliance (Cdyn), platform pressure (Pplat), and airway peak pressure (Ppeak)]. The average was taken after multiple measurements. The specific operations were performed as per the instructions of the instrument, and the obtained values were analyzed according to the instructions provided by manufacturers.

Statistical analysis

All raw experimental data were processed by Statistical Product and Service Solutions (SPSS) 19.0 analysis software (SPSS Inc., Chicago, IL, USA) and subjected to multiple comparisons. The experimental results obtained were expressed as mean ± standard deviation (x±SD), and P<0.05 suggested that the difference was statistically significant. Graphpad Prism 5.0 (La Jolla, CA, USA) was applied for plotting histograms.

Results

Hemodynamic indexes detected

As shown in Table II, the MAP, HR and SpO2 exhibited no obvious differences at each observation time point among three groups (P>0.05), suggesting that there is no impact on hemodynamics during OLV.

Levels of inflammatory factors detected

At T2 and T3, the levels of serum IL-6, TNF-\alpha and IL-8 showed marked decreases in group D1 and D2 compared with those in group C (P<0.05), and the decreases were overtly larger in group D1 than those in group D2, and they were evidently greater at T3 than those at T2 (P<0.05) (Table III).

Table II  Hemodynamic indexes.

<table>
<thead>
<tr>
<th>Group</th>
<th>MAP</th>
<th>HR</th>
<th>SpO2 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group C at T0</td>
<td>79.9±1.0</td>
<td>81.5±1.1</td>
<td>89.1±0.8</td>
</tr>
<tr>
<td>T1</td>
<td>79.5±1.1</td>
<td>80.1±1.2</td>
<td>87.2±0.1</td>
</tr>
<tr>
<td>T2</td>
<td>79.0±1.2</td>
<td>81.4±1.1</td>
<td>85.8±0.4</td>
</tr>
<tr>
<td>T3</td>
<td>79.2±1.3</td>
<td>81.6±1.5</td>
<td>85.3±0.4</td>
</tr>
<tr>
<td>Group D1 at T0</td>
<td>78.8±1.1</td>
<td>80.9±1.0</td>
<td>85.7±0.9</td>
</tr>
<tr>
<td>T1</td>
<td>78.9±1.8</td>
<td>81.8±1.6</td>
<td>86.1±0.8</td>
</tr>
<tr>
<td>T2</td>
<td>78.5±1.9</td>
<td>80.5±1.7</td>
<td>85.1±0.6</td>
</tr>
<tr>
<td>T3</td>
<td>77.1±1.2</td>
<td>78.4±1.8</td>
<td>95.9±0.9</td>
</tr>
<tr>
<td>Group D2 at T0</td>
<td>78.8±1.3</td>
<td>79.5±1.2</td>
<td>85.3±0.8</td>
</tr>
<tr>
<td>T1</td>
<td>78.2±1.7</td>
<td>79.8±1.7</td>
<td>85.9±0.9</td>
</tr>
<tr>
<td>T2</td>
<td>80.2±3.0</td>
<td>79.7±2.1</td>
<td>84.5±0.3</td>
</tr>
<tr>
<td>T3</td>
<td>76.4±1.5</td>
<td>77.0±1.1</td>
<td>90.5±0.1</td>
</tr>
</tbody>
</table>

Note: No evident differences are detected in the MAP, HR and SpO2 among the three groups at each observation time point (P>0.05). MAP: mean arterial pressure; HR: heart rate; SpO2: pulse oxygen saturation.
Results of oxidative stress determination

According to Table IV, group D1 and D2 showed notably declined levels of serum ROS and MDA (P<0.05) and overtly raised SOD content (P<0.05) at T2 and T3 in comparison with group C, and the effects were markedly better in group D1 than those in group D2, and they were significantly superior at T3 to those at T2 (P<0.05).

PaO2 and the intrapulmonary shunt Qs/Qt

As shown in Table VI, group D1 and D2 had notably lowered Qs/Qt (P<0.05) and overtly elevated PaO2 content (P<0.05) at T2 and T3 in comparison with group C, and the decline and increase were markedly greater in group D1 than those in group D2, and they were significantly larger at T3 than those at T2 (P<0.05).

Lung function indexes detected

The results of lung function index detection (Table VII) revealed that the Cdyn, Pplat and Ppeak displayed no significant differences among three groups at T0 and T1. At T2 and T3, the Cdyn was evidently raised, while the Pplat and Ppeak overtly declined (P<0.05). Moreover, group D1 had better effects in comparison with group D2, and the effects were obviously superior at T3 to those at T2 (P<0.05).

Table III Levels of serum IL-6, TNF-α and IL-8.

<table>
<thead>
<tr>
<th>Group</th>
<th>IL-8 (mg/L)</th>
<th>TNF-α (mg/L)</th>
<th>IL-6 (mg/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group C at T0</td>
<td>58.9±1.7</td>
<td>38.6±1.0</td>
<td>46.8±1.9</td>
</tr>
<tr>
<td>T1</td>
<td>62.2±1.1</td>
<td>40.6±1.1</td>
<td>48.6±1.7</td>
</tr>
<tr>
<td>T2</td>
<td>65.7±1.9</td>
<td>42.5±1.3</td>
<td>49.4±1.6</td>
</tr>
<tr>
<td>T3</td>
<td>69.4±1.3</td>
<td>45.8±1.7</td>
<td>50.4±1.5</td>
</tr>
<tr>
<td>Group D1 at T0</td>
<td>59.9±1.5</td>
<td>40.3±1.1</td>
<td>46.9±1.7</td>
</tr>
<tr>
<td>T1</td>
<td>48.5±1.4A</td>
<td>38.1±1.4A</td>
<td>33.1±2.0A</td>
</tr>
<tr>
<td>T2</td>
<td>27.2±1.5abA</td>
<td>25.1±1.2abA</td>
<td>23.3±2.2abA</td>
</tr>
<tr>
<td>T3</td>
<td>21.6±1.1abcA</td>
<td>9.5±1.7abcA</td>
<td>10.5±2.5abcA</td>
</tr>
<tr>
<td>Group D2 at T0</td>
<td>58.7±1.9</td>
<td>41.2±1.7</td>
<td>47.8±1.4</td>
</tr>
<tr>
<td>T1</td>
<td>52.4±1.5A</td>
<td>37.2±1.6A</td>
<td>39.7±2.5A</td>
</tr>
<tr>
<td>T2</td>
<td>37.8±1.6abAB</td>
<td>29.4±1.4abAB</td>
<td>30.8±2.6abAB</td>
</tr>
<tr>
<td>T3</td>
<td>27.9±1.7abcAB</td>
<td>17.4±1.8abcAB</td>
<td>16.0±2.7abcAB</td>
</tr>
</tbody>
</table>

Note: The levels of serum IL-6, TNF-α and IL-8 display remarkably decreases in group D1 and D2 compared with those in group C (P<0.05) at T2 and T3, and the decreases are overtly larger in group D1 than those in group D2, and they are evidently greater at T3 than those at T2 (P<0.05). Intra-group comparison: aP<0.05 vs. T0, bP<0.05 vs. T1, and cP<0.05 vs. T2. Inter-group comparison: AP<0.05 vs. group C, and bP<0.05 vs. group D1.

Table IV Content of serum ROS, MDA and SOD.

<table>
<thead>
<tr>
<th>Group</th>
<th>ROS (U/L)</th>
<th>MDA (mmol/L)</th>
<th>SOD (U/mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group C at T0</td>
<td>30.5±1.4</td>
<td>16.5±1.8</td>
<td>4.1±1.0</td>
</tr>
<tr>
<td>T1</td>
<td>32.5±1.7</td>
<td>17.6±1.4</td>
<td>3.4±1.4</td>
</tr>
<tr>
<td>T2</td>
<td>33.7±1.8</td>
<td>18.2±1.1</td>
<td>3.8±1.5</td>
</tr>
<tr>
<td>T3</td>
<td>34.8±1.9</td>
<td>17.0±1.3</td>
<td>4.3±1.2</td>
</tr>
<tr>
<td>Group D1 at T0</td>
<td>31.1±1.8</td>
<td>17.2±1.4</td>
<td>4.2±1.8</td>
</tr>
<tr>
<td>T1</td>
<td>28.1±1.7A</td>
<td>15.2±1.0A</td>
<td>6.8±1.4A</td>
</tr>
<tr>
<td>T2</td>
<td>18.4±1.4abA</td>
<td>10.5±1.0abA</td>
<td>12.6±1.6abA</td>
</tr>
<tr>
<td>T3</td>
<td>7.6±1.9abcA</td>
<td>4.6±1.1abcA</td>
<td>21.5±1.5abcA</td>
</tr>
<tr>
<td>Group D2 at T0</td>
<td>31.5±1.3</td>
<td>17.9±1.8</td>
<td>4.0±1.6</td>
</tr>
<tr>
<td>T1</td>
<td>27.8±1.8A</td>
<td>16.2±1.4A</td>
<td>5.2±1.4A</td>
</tr>
<tr>
<td>T2</td>
<td>22.1±1.1abAB</td>
<td>13.5±1.3abAB</td>
<td>8.6±1.8abAB</td>
</tr>
<tr>
<td>T3</td>
<td>14.6±1.5abcAB</td>
<td>8.4±1.0abcAB</td>
<td>15.8±1.3abcAB</td>
</tr>
</tbody>
</table>

Note: Compared with those in group C, the levels of serum ROS and MDA are prominently decreased (P<0.05) in group D1 and D2 at T2 and T3, while the SOD content is remarkably elevated (P<0.05), and the effects are markedly better in group D1 than those in group D2, and they are significantly superior at T3 to those at T2 (P<0.05). Intra-group comparison: aP<0.05 vs. T0, bP<0.05 vs. T1, and cP<0.05 vs. T2. Inter-group comparison: AP<0.05 vs. group C, and bP<0.05 vs. group D1.

Table V SctO2 in different groups.

<table>
<thead>
<tr>
<th>Group</th>
<th>T0</th>
<th>T1</th>
<th>T2</th>
<th>T3</th>
</tr>
</thead>
<tbody>
<tr>
<td>SctO2 (%)</td>
<td>Group C</td>
<td>81.5±1.5</td>
<td>70.5±1.0A</td>
<td>65.5±1.2ab</td>
</tr>
<tr>
<td>Group D1</td>
<td>82.1±1.1</td>
<td>80.7±1.6A</td>
<td>76.8±1.6abA</td>
<td>70.1±1.9abcA</td>
</tr>
<tr>
<td>Group D2</td>
<td>80.1±1.6</td>
<td>75.1±1.6AB</td>
<td>70.8±1.7abcA</td>
<td>65.1±1.9bcAB</td>
</tr>
</tbody>
</table>

Note: The SctO2 is significantly lowered in group D1 and D2 at T2 and T3 compared with that at T0 and T1, and the decrease in group D1 is distinctly smaller than that in group D2 (P<0.05). Intra-group comparison: aP<0.05 vs. T0, bP<0.05 vs. T1, and cP<0.05 vs. T2. Inter-group comparison: AP<0.05 vs. group C, and bP<0.05 vs. group D1.
Table VI PaO2 and the intrapulmonary shunt Qs/Qt.

<table>
<thead>
<tr>
<th>Group</th>
<th>PaO2 (mmHg)</th>
<th>Qs/Qt (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group C at T0</td>
<td>80.5±1.5</td>
<td>31.5±1.7</td>
</tr>
<tr>
<td>T1</td>
<td>285.1±1.7a</td>
<td>32.4±1.5</td>
</tr>
<tr>
<td>T2</td>
<td>186.1±1.6ab</td>
<td>33.9±1.6</td>
</tr>
<tr>
<td>T3</td>
<td>152.6±1.9abcA</td>
<td>31.0±1.1</td>
</tr>
<tr>
<td>Group D1 at T0</td>
<td>81.5±1.0</td>
<td>32.1±1.5</td>
</tr>
<tr>
<td>T1</td>
<td>185.4±1.9aA</td>
<td>30.1±1.2A</td>
</tr>
<tr>
<td>T2</td>
<td>100.8±1.4abA</td>
<td>15.4±1.4abA</td>
</tr>
<tr>
<td>T3</td>
<td>130.9±1.5abcA</td>
<td>5.9±1.3abcA</td>
</tr>
<tr>
<td>Group D2 at T0</td>
<td>83.1±1.7</td>
<td>31.9±1.7</td>
</tr>
<tr>
<td>T1</td>
<td>180.4±1.5aA</td>
<td>29.1±1.5</td>
</tr>
<tr>
<td>T2</td>
<td>91.5±1.7abAB</td>
<td>20.1±1.8abAB</td>
</tr>
<tr>
<td>T3</td>
<td>110.6±1.9abcAB</td>
<td>10.4±1.9abcAB</td>
</tr>
</tbody>
</table>

Note: The Qs/Qt is significantly lower in group D1 and D2 than that in group C at T2 and T3 (P<0.05), while the PaO2 content is notably raised (P<0.05), and such decrease and increase are significantly larger in group D1 than those in D2 group, and they are obviously greater at T3 than those at T2 (P<0.05). Intra-group comparison: aP<0.05 vs. T0, bP<0.05 vs. T1, and cP<0.05 vs. T2. Inter-group comparison: aP<0.05 vs. group C, and bP<0.05 vs. group D1.

Table VII Lung function indexes detected.

<table>
<thead>
<tr>
<th>Group</th>
<th>Cdyn (mL/cm H2O)</th>
<th>Pplat (cm H2O)</th>
<th>Ppeak (cm H2O)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group C at T0</td>
<td>25.3±2.2</td>
<td>34.5±2.8</td>
<td>30.5±2.2</td>
</tr>
<tr>
<td>T1</td>
<td>26.3±2.7</td>
<td>33.4±2.4</td>
<td>29.4±2.8</td>
</tr>
<tr>
<td>T2</td>
<td>27.8±2.5</td>
<td>30.1±2.9</td>
<td>28.4±2.4</td>
</tr>
<tr>
<td>T3</td>
<td>28.1±2.9</td>
<td>29.8±2.0</td>
<td>27.6±2.5</td>
</tr>
<tr>
<td>Group D1 at T0</td>
<td>26.3±2.0</td>
<td>35.7±2.0</td>
<td>31.4±1.2</td>
</tr>
<tr>
<td>T1</td>
<td>28.4±2.8</td>
<td>30.4±2.7</td>
<td>30.1±1.8</td>
</tr>
<tr>
<td>T2</td>
<td>40.8±2.9abA</td>
<td>18.4±2.9abA</td>
<td>19.4±1.3abA</td>
</tr>
<tr>
<td>T3</td>
<td>52.7±2.3abcA</td>
<td>8.4±2.3abcA</td>
<td>9.1±1.3abcA</td>
</tr>
<tr>
<td>Group D2 at T0</td>
<td>25.9±2.1</td>
<td>35.1±2.4</td>
<td>31.8±2.0</td>
</tr>
<tr>
<td>T1</td>
<td>26.9±2.7</td>
<td>30.4±2.6</td>
<td>30.5±1.0</td>
</tr>
<tr>
<td>T2</td>
<td>34.8±2.1abcAB</td>
<td>24.6±2.8abcAB</td>
<td>25.8±1.6abcAB</td>
</tr>
<tr>
<td>T3</td>
<td>44.8±2.4abcAB</td>
<td>16.7±2.0abcAB</td>
<td>17.6±1.9abcAB</td>
</tr>
</tbody>
</table>

Note: At T0 and T1, there are no significant differences in the Cdyn, Pplat and Ppeak among three groups. At T2 and T3, the Cdyn is significantly elevated, while the Pplat and Ppeak overly decline (P<0.05), and group D1 has better effects in comparison with group D2, and the effects are obviously superior at T3 to those at T2 (P<0.05). Intra-group comparison: aP<0.05 vs. T0, bP<0.05 vs. T1, and cP<0.05 vs. T2. Inter-group comparison: aP<0.05 vs. group C, and bP<0.05 vs. group D1.

Discussion

Hypoxemia is caused bright-to-left shunt and uneven distribution of alveolar ventilation and pulmonary perfusion in lungs, and the high ventilation/perfusion area interferes in the effective clearance of CO2, which may result in hypercapnia (15). OLV will aggravate intrapulmonary shunt and dead space, while gravity and HPV confer protective effects (16). Besides, treatment strategies for OLV-induced hypoxemia, such as positive end-expiratory pressure ventilation and recruitment of alveoli, are not very effective in inhibiting the progression of the disease. In addition to the β-adrenergic receptors in bronchial smooth muscle, there are α1- and α2-adrenergic receptors expressed in the bronchial mucosa and ganglia (17). The bronchodilators currently used target the β-adrenergic receptors in the bronchial wall, and the effects of the bronchodilators targeting the α-adrenergic receptors have not been verified. Dexmedetomidine, a selective α-adrenergic receptor agonist, is reported to effectively repress histamine-induced bronchoconstriction and reduce the intrapulmonary shunt in healthy patients during OLV in an animal study (18). What’s more, it is known that dexmedetomidine is capable of directly lowering pulmonary artery pressure, and will not increase pulmonary artery pressure in patients with pulmonary hypertension (19). Vickovic et al. (20) found that magnesium sulfate as an adjuvant to anesthesia in patients with arterial hypertension reduces hemodynamic changes during anesthesia. It was found in this study that there were no evident differences in the MAP, HR and SpO2 among three groups at each observation time point, indicating that there is no influence on hemodynamics during OLV. ROS plays an important role in various tissue damage like liver damage. Reactive oxygen radicals have been associated with many diseases including autoimmune diseases like rheumatoid arthritis, diabetes mellitus, atherosclerosis, obesity, hypertension and cardiovascular diseases such as ischemia (21, 22). It can also trigger a cascade of cell damage and necrosis/apoptosis and subsequent pro-inflammatory response, further facilitating the progression of diseases (23). In this study, it was discovered that the serum IL-6, TNF-α and IL-8 levels were markedly down-regulated in group D1 and D2 compared with those in group C at T2 and T3, and the decreases were overtly larger in group D1 than those in group D2, and they were evidently greater at T3 than those at T2. Besides, the serum ROS and MDA levels were clearly reduced, while the SOD content obviously rose in group D1 and D2 at T2 and T3 compared with those in group C. Additionally, the effects were markedly better in group D1 than those in group D2, and they were significantly superior at T3 to those at T2.

In abdominal surgeries, anesthesia management based on brain saturation monitoring is able to shorten hospital stays and reduce cognitive dysfunc-
tion. In abdominal surgeries for the elderly, decreased cerebral blood oxygen level is almost always correlated with massive or continued hemorrhage and significantly down-regulated hemoglobin level (24). The results of this study manifested that the \( S_{O2} \) was evidently lowered in group D1 and D2 at T2 and T3 compared with that at T0, and the decrease in group D1 was distinctly smaller than that in group D2. \( PaO_2 \) triggers the contraction of capillaries by inhibiting the nitric oxide and cyclooxygenase pathways. Anesthetics and techniques may affect shunt by altering cardiac output, pulmonary vascular tone and modification of HPV. Furthermore, hemodynamic parameters and anesthesia needs are measured and evaluated as secondary outcomes, which may have effects on shunt (25, 26). Elhamik et al. (27) studied the effect of infusion of dexmedetomidine and found that dexmedetomidine reduces the shunt and improves oxygenation, and patients receiving epidural anesthesia with dexmedetomidine have lowered bispectral index values, intraoperative awareness and need for analgesia. It was found in this study that at T2 and T3, the Qs/Qt was overtly lowered, while the \( PaO_2 \) content was significantly elevated in group D1 and D2 compared with those in group C, and the effects were markedly better in group D1 than those in group D2, and they were significantly superior at T3 to those at T2. Moreover, an animal study revealed that dexmedetomidine increases pulmonary artery pressure and pulmonary vascular resistance via direct effects of its receptors on the vascular smooth muscle. Similar changes are also observed in healthy volunteers when the plasma concentration of dexmedetomidine infused reaches 1.9 ng/mL (27). In this study, it was revealed that no significant differences were detected in the Cdyn, Pplat and Ppeak among three groups at T0 and T1. At T2 and T3, the Cdyn was notably raised, while the Pplat and Ppeak were overtly reduced, and group D1 had overtly better effects in comparison with group D2, and the effects were obviously superior at T3 to those at T2. The results of this study are similar to the findings of above studies.

Conclusions

According to our results, the present study demonstrated that dexmedetomidine is able to effectively mitigate inflammatory response and oxidative stress, lower oxygenation and Qs/Qt and improve \( S_{O2} \) and lung function during OLV with good effects. Our study found that patients undergoing open pulmonary lobectomy and observing hemodynamic parameters, inflammatory factors, oxidative stress indicators, and changes in \( S_{O2} \), \( PaO_2 \) and Qs/Qt as well as lung function at different time points, provides theoretical and experimental bases for the popularization and application of dexmedetomidine. Although our study provided a good experimental basis for the research and development of adrenergic receptor drugs, further studies in dexmedetomidine patients are still required for indications of antioxidative therapy during anaesthesia.

Acknowledgements. No.

Conflict of interest statement

The authors reported no conflict of interest regarding the publication of this article.

References

10. Chen Z, Ding T, Ma CG. Dexmedetomidine (DEX) protects against hepatic ischemia/reperfusion (I/R) injury by


Received: September 19, 2021
Accepted: November 11, 2021